AbbVie (ABBV) Common Equity (2012 - 2026)
AbbVie (ABBV) posted quarterly Common Equity of -$6.7 billion for Q1 2026, down 555.27% year-over-year from $1.5 billion in Q1 2025, and down 103.55% quarter-over-quarter from -$3.3 billion in Q4 2025.
AbbVie (ABBV) Common Equity (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Common Equity for 15 consecutive years, with -$6.7 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 555.27% year-over-year to -$6.7 billion; the TTM figure through Mar 2026 stood at -$6.7 billion (down 555.27% YoY), while the FY2025 annual figure was -$3.3 billion, down 197.21% from the prior year.
- Common Equity declined to -$6.7 billion in Q1 2026 per ABBV's latest filing, from -$3.3 billion in the prior quarter.
- Across five years, Common Equity topped out at $17.3 billion in Q4 2022 and bottomed at -$6.7 billion in Q1 2026.
- Historically, Common Equity has averaged $7.4 billion across 5 years, with a median of $8.0 billion in 2024.
- Annual changes were most pronounced in 2022 — Common Equity gained 18.79% — and 2026, when it tumbled 555.27%.
- AbbVie's Common Equity stood at $17.3 billion in 2022, then plunged by 39.86% to $10.4 billion in 2023, then sank by 67.64% to $3.4 billion in 2024, then plunged by 197.21% to -$3.3 billion in 2025, then sank by 103.55% to -$6.7 billion in 2026.
- Business Quant data shows ABBV's Common Equity at -$6.7 billion in Q1 2026, -$3.3 billion in Q4 2025, and -$2.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 80.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.94 Bn |
| Mar 31, 2026 | -6.66 Bn |
| Dec 31, 2025 | -3.27 Bn |
| Sep 30, 2025 | -2.64 Bn |
| Jun 30, 2025 | -138.00 Mn |
| Mar 31, 2025 | 1.46 Bn |
| Dec 31, 2024 | 3.36 Bn |
| Sep 30, 2024 | 6.07 Bn |
| Jun 30, 2024 | 6.82 Bn |
| Mar 31, 2024 | 8.05 Bn |
| Dec 31, 2023 | 10.40 Bn |
| Sep 30, 2023 | 12.13 Bn |
| Jun 30, 2023 | 12.90 Bn |
| Mar 31, 2023 | 13.30 Bn |
| Dec 31, 2022 | 17.29 Bn |
| Sep 30, 2022 | 16.03 Bn |
| Jun 30, 2022 | 14.69 Bn |
| Mar 31, 2022 | 16.31 Bn |
| Dec 31, 2021 | 15.44 Bn |
| Sep 30, 2021 | 13.58 Bn |